Headache News and Research

Latest Headache News and Research

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable system for severe headaches, today announced positive preliminary findings from a study evaluating the safety and efficacy of the company's investigational neurostimulation system for the treatment of cluster headache.

27 Jun 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

24 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

MAP to present LEVADEX data on migraine at 15th Congress of IHC

MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.

23 Jun 2011

St. Jude Medical announces results of Genesis neurostimulator trial on chronic migraine

St. Jude Medical, Inc., a global medical device company, today announced study results on the safety and efficacy of peripheral nerve stimulation (PNS) of the occipital nerve for the management of pain and disability associated with chronic migraine, a debilitating condition that affects millions worldwide.

23 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

New anti-abuse formulation of painkiller Oxycodone

It has come to health officials’ attention nationwide that there is a serious rise of abuse of painkillers, especially opioids. Federal officials recently stepped up plans to monitor frequent prescribers and users.

21 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Acura, Pfizer receive FDA approval for OXECTA Tablets to manage severe pain

Pfizer Inc. and Acura Pharmaceuticals Inc. announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM Tablets CII.

20 Jun 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx, Inc., announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.

20 Jun 2011

Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany's healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by Enterohemorrhagic Escherichia coli in an unusually wide outbreak in Germany that began in May.

20 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

WHO special issue addresses economic burden of dengue in the Americas, Africa and Asia

The ten studies in this special issue document the substantial and growing burden of dengue in the Americas, Africa and Asia, and the burden of a chikungunya outbreak in India.

18 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that the positive results from REVIVE-RP, a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Study explains why some people experience repeated infections of Lyme disease

The bacteria that cause Lyme disease, one of the most important emerging diseases in the United States, appear to hide out in the lymph nodes, triggering a significant immune response, but one that is not strong enough to rout the infection, report researchers at the University of California, Davis.

17 Jun 2011

Headache News and Research

Latest Headache News and Research

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

EMA CHMP recommends approval of linagliptin for type 2 diabetes

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

MAP to present LEVADEX data on migraine at 15th Congress of IHC

St. Jude Medical announces results of Genesis neurostimulator trial on chronic migraine

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

New anti-abuse formulation of painkiller Oxycodone

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Acura, Pfizer receive FDA approval for OXECTA Tablets to manage severe pain

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome

FDA approves NULOJIX

WHO special issue addresses economic burden of dengue in the Americas, Africa and Asia

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Study explains why some people experience repeated infections of Lyme disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in